Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NHI Prices Recommended for Approval for 6 Products
September 12, 2005
- Medical Expenditure for Clinics Rose 2.5% in FY2004: HIB
September 12, 2005
- AstraZeneca Aims for 4.2% Share of Domestic Market by 2010
September 12, 2005
- R&D NEWS IN BRIEF
September 12, 2005
- SELF-MEDICATION NEWS IN BRIEF
September 12, 2005
- Statistics
September 12, 2005
- COMMENTARY 6 articles
September 12, 2005
- Tonic Drinks: Sales of New Quasi-drugs Outpace OTC Products
September 5, 2005
- Uncollected Medical Fees - Why Don't Patients Pay?
September 5, 2005
- HUMAN RESOURCE NEWS IN BRIEF
September 5, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 5, 2005
- 1st Qtr Business Results
September 5, 2005
- JMACCT to Determine Number of Patients Seen by Each Institution by Disease
September 5, 2005
- BUSINESS NEWS IN BRIEF
September 5, 2005
- New Regenerative Therapy Using Cell Sheets Reported: Dr Okano
September 5, 2005
- Merger Preparations Going Smoothly: Sumitomo Pharm.
September 5, 2005
- SMOs Expected to Outpace CROs in Future Growth: Seminar
September 5, 2005
- Takeda Preparing to Launch Rozerem in US
September 5, 2005
- R&D NEWS IN BRIEF
September 5, 2005
- REGULATORY NEWS IN BRIEF
September 5, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…